MedicaidPrior AuthMedium impact
MAB2024110606
Pennsylvania Medicaid (DHS)·PA · Neurology, Family Medicine, Internal Medicine +1 more·Provider Bulletin
Effective date
Jan 6, 2025
We identified it
Jun 20, 2026
Summary
Pennsylvania Medical Assistance (Medicaid) is implementing new prior authorization requirements for migraine acute treatment agents including gepants, ditans, and ergot alkaloids. Key changes include requiring therapeutic failure of preferred agents before approving non-preferred ones, and new guidelines for prescription renewals and therapeutic duplications.
Action Required
By January 6, 2025: Billing and clinical teams must update prior authorization procedures for migraine medications in Pennsylvania Medicaid patients. Ensure prescribers document therapeutic failure of preferred triptans before prescribing gepants, ditans, or ergot alkaloids. Update encounter forms to capture contraindications and treatment history. Verify all migraine acute treatment prescriptions meet new medical necessity criteria including age-appropriate dosing and FDA-approved indications. Claims may be denied without proper prior authorization documentation.